Literature DB >> 7770630

Are enterochromaffinlike cell tumours reversible? An experimental study on gastric carcinoids induced in Mastomys by histamine2-receptor blockade.

B Wängberg1, O Nilsson, E Theodorsson, I M Modlin, A Dahlström, H Ahlman.   

Abstract

A rapid induction of enterochromaffinlike (ECL) cell tumours has been shown in Praomys (Mastomys) natalensis subjected to histamine2-receptor blockade. In the present study the reversibility of ECL cell proliferation induced by acid inhibition was investigated. Short-term treatment (8 weeks) with the histamine2-receptor antagonist loxtidine caused a moderate hypergastrinemia, accompanied by a minor increase in histamine contents and a 2-fold increased volume density of the endocrine cells in gastric oxyntic mucosa. Eight weeks after withdrawal of treatment the volume density of endocrine cells was normalised as were the tissue levels of histamine, indicating a total reversibility of ECL cell hyperplasia. Long-term treatment (24 weeks) caused severe changes in the endocrine cell population of the oxyntic mucosa with neoplasia (5/21), dysplasia (11/21) and nodular hyperplasia (5/21). The endocrine cell density increased twofold and tissue histamine levels fourfold. 24 weeks after cessation of treatment, the endocrine cell density had decreased to 136% of controls, while histamine concentrations were normalised. The frequency of invasive carcinoids after recovery (4/23) differed only slightly from that seen after treatment for 24 weeks (5/21). Dysplastic lesions were only seen in 1/23 and hyperplastic lesions were of less severe type after recovery. The results demonstrate that ECL cell hyperplasia and dysplasia, induced by acid inhibition, are reversible after cessation of treatment. However, ECL cell tumours did not disappear, within the given observation period. One may therefore speculate that ECL cell proliferation is no longer reversible once the neoplastic (transformed) phenotype has developed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7770630     DOI: 10.1016/0167-0115(95)00123-s

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  8 in total

1.  Ultrastructure of ECL cells in Mastomys after long-term treatment with H2 receptor antagonist loxtidine.

Authors:  Reidar Alexander Vigen; Mark Kidd; Irvin M Modlin; Duan Chen; Chun-Mei Zhao
Journal:  Med Mol Morphol       Date:  2012-06       Impact factor: 2.309

2.  Mechanism of acid hypersecretion post curative gastrinoma resection.

Authors:  Jeremiah V Ojeaburu; Tetsuhide Ito; Pellegrino Crafa; Cesare Bordi; Robert T Jensen
Journal:  Dig Dis Sci       Date:  2010-08-20       Impact factor: 3.199

3.  Changes of the gastric endocrine cells in the C57BL/6 mouse after implantation of murine lung carcinoma: an immunohistochemical quantitative study.

Authors:  Sae-Kwang Ku; Hyeung-Sik Lee; Joon-Seok Byun; Bu-Il Seo; Jae-Hyun Lee
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

4.  Changes of the intestinal endocrine cells in the C57BL/6 mouse after implantation of murine lung carcinoma (3LL): an immunohistochemical quantitative study.

Authors:  Sae-Kwang Ku; Seung-Kyoo Seong; Dae-Young Kim; Hyeung-Sik Lee; Jong-Dae Kim; Hae-Yun Choi; Bu-Il Seo; Jae-Hyun Lee
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

Review 5.  Animal models to study the role of long-term hypergastrinemia in gastric carcinogenesis.

Authors:  Reidar Fossmark; Gunnar Qvigstad; Tom Chr Martinsen; Øyvind Hauso; Helge L Waldum
Journal:  J Biomed Biotechnol       Date:  2010-11-24

Review 6.  Histamine metabolism of gastric carcinoids in Mastomys natalensis.

Authors:  L Kölby; B Wängberg; H Ahlman; I M Modlin; O Nilsson
Journal:  Yale J Biol Med       Date:  1998 May-Aug

Review 7.  Relationship of ECL cells and gastric neoplasia.

Authors:  H L Waldum; E Brenna; A K Sandvik
Journal:  Yale J Biol Med       Date:  1998 May-Aug

Review 8.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.